CHA Bio Group to display cell, gene therapy abilities at BIO USA
![CHA Bio Group and its U.S. cell and gene therapy company, Matica Biotechnology, will participate in the upcoming Bio International Convention 2024. [CHA BIO GROUP]](https://koreajoongangdaily.joins.com/data/photo/2024/05/21/50688254-563f-415f-943b-cb319dc11cca.jpg)
CHA Bio Group and its U.S. cell and gene therapy company, Matica Biotechnology, will participate in the upcoming Bio International Convention 2024. [CHA BIO GROUP]
CHA Bio Group plans to set up two booths during this year’s BIO USA, which will run from June 3 to 6 in San Diego, one for its U.S. cell and gene therapy subsidiary Matica Biotechnology, and another for the parent company.
Matica’s exhibition booth will be located among other contract development and manufacturing organization (CDMO) companies. Matica completed construction of its CDMO facility for cell and gene therapies in Texas, and introduced its MatiMax cell line during last year’s BIO USA convention held in Boston.
As a committee of the U.S. House of Representatives recently approved a bill dubbed the Biosecure Act, which aims to reduce the country’s reliance on Chinese technologies while bringing manufacturing capabilities back to the United States, Matica hopes to leverage its production capabilities in the country during the upcoming convention. The company has so far booked meetings with more than 30 potential clients.
CHA Bio Group’s booth will feature core technologies from CHA Biotech, CMG Pharmaceutical and CHA Vaccine Institute, including CHA Biotech’s immune cell therapy candidate CBT101, which is currently under development.
“As overseas biopharmaceutical players are expanding their research and development investments, the business environment across the industry is improving,” said CHA Biotech CEO Oh Sang-hoon, adding that “CHA Bio Group will introduce its strength in cell therapy and the CDMO business during BIO USA, and make strides into the global market.”
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)